Anavex Life Sciences Corp (AVXL)

[Trainguy1]

I think next month could be pivotal following completion and release of top line results for PDD OLE. If safety is confirmed, and dementia, sleep, & parkinsonian movement issues prove to be stablized or improved since the end of ph2 at least for patients with wild type sigma-1 receptors, then A2-73 may be acceptable for NDA submittal.